6/13/2014 12:45:03 PM
WORCESTER, Mass. and TORONTO, June 12, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (
http://globalmessaging1.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=7743641&adr_order=3455&url=aHR0cDovL3d3dy5nZW5lcmV4LmNvbS8%3D> ) (OTCBB:GNBT) today announced an interview given by Dr. Elizabeth Mittendorf, M.D., Ph.D. Dr. Mittendorf is the Principal Investigator of the AE37 clinical trial to test the ability of the novel immunotherapeutic agent to prevent relapse in patients who have had HER2-expressing breast cancer, the largest Phase IIb peptide clinical trial conducted to date. AE37 is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (
www.antigenexpress.com <http://globalmessaging1.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=7743641&adr_order=3455&url=aHR0cDovL3d3dy5hbnRpZ2VuZXhwcmVzcy5jb20v> ). The interview was conducted by Oncology TV at this year's Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from May 30 to June 3. The interview can be viewed online at:
Dr. Mittendorf, Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, noted during the interview that the Phase II trial of AE37 in breast cancer patients had accomplished what it was intended to do: establishing that it was safe, well tolerated, and identified the patient groups that would benefit most from the AE37 vaccine in terms of preventing relapse. In particular, she noted that patients with low HER2 expression, who are not eligible for Herceptin, and especially triple negative patients, appeared to benefit the most. She further pointed out that patients were generally enthusiastic to receive the vaccine, indicating that it was given at a time when standard of care therapy was completed and there was really nothing more for patients to do but wait. The current data showed a 40% reduction of relapse in patients with low HER2 tumors and a 60% reduction in patients with triple negative breast cancer.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com < http://globalmessaging1.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=7743641&adr_order=3455&url=aHR0cDovL3d3dy5nZW5lcmV4LmNvbS8%3D> or the Antigen Express website at www.antigenexpress.com < http://globalmessaging1.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=7743641&adr_order=3455&url=aHR0cDovL3d3dy5hbnRpZ2VuZXhwcmVzcy5jb20v> .
Help employers find you! Check out all the jobs and post your resume.
comments powered by